ReviewNature reviews. Cancer2025
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.
Review in Nature reviews. Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neutrophil-to-lymphocyte ratio as a prognostic biomarker in lung cancer patients treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
- Applications and challenges of biomarker-based predictive models in proactive health management.Frontiers in public health · 2025Pooled it
- Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial.Signal transduction and targeted therapy · 2026Trial
- Causal relationship between oral microbiome, circulating inflammatory proteins and lung cancer: A Mendelian randomization study.Medicine · 2026Article
- DONSON links tumor-cell survival to MIF-associated macrophage remodeling in small cell lung cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- Article
- OX40 (TNFRSF4) Tracks Immune Infiltration in Small Cell Lung Cancer and Shows a Cohort-Specific, Non-Replicated Association with the POU2F3/SCLC-P Subtype: A Multi-Source In Silico Analysis.International journal of molecular sciences · 2026Article
- Association between antibiotic exposure and outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: a single-center retrospective cohort study.Translational lung cancer research · 2026Article
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- Deconvolution of evolutionary architecture unmasks a high-risk, subclonal-rich subtype in treatment-naive small cell lung cancer.Journal of thoracic disease · 2026Article
- Development and validation of a radiomics-habitat model for preoperatively predicting poorly differentiated stage IA lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Exosome-delivered pepDCBLD2 promotes glucose metabolism to induce chemoresistance in colon cancer.Journal of translational medicine · 2026Article
- Role of epithelial-mesenchymal transition (EMT) in malignancies: current status and future prospects.Signal transduction and targeted therapy · 2026Review
- From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics.Signal transduction and targeted therapy · 2026Article
- Revisiting Platinum Sensitivity in Relapsed Small-Cell Lung Cancer: Outcomes of Platinum-Containing Doublet Chemotherapy in the 3-6 Month Relapse Window.Current oncology (Toronto, Ont.) · 2026Article
- Ginsenoside Rh2 inhibits non-small-cell lung cancer malignant progression through targeting AURKA.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- MYC in Oncogenesis and Therapeutic Implications.MedComm · 2026Review
- [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- A USP15/KRT17-associated 13-gene prognostic cluster and functional validation in EGFR-mutant lung adenocarcinoma.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with ~7% 5-year overall survival reflecting early metastasis and rapid acquired chemoresistance. Immunotherapy briefly extends overall survival in ~15% cases, yet predictive biomarkers are lacking. Targeted therapies are beginning to show promise, with a recently approved delta-like ligand 3 (DLL3)-targeted therapy impacting the treatment landscape. The increased availability of patient-faithful models, accumulating human tumour biobanks and numerous comprehensive molecular profiling studies have collectively facilitated the mapping and understanding of substantial intertumoural and intratumoural heterogeneity. Beyond the almost ubiquitous loss of wild-type p53 and RB1, SCLC is characterized by heterogeneously mis-regulated expression of MYC family members, yes-associated protein 1 (YAP1), NOTCH pathway signalling, anti-apoptotic BCL2 and epigenetic regulators. Molecular subtypes are based on the neurogenic transcription factors achaete-scute homologue 1 (ASCL1) and neurogenic differentiation factor 1 (NEUROD1), the rarer non-neuroendocrine transcription factor POU class 2 homeobox 3 (POU2F3), and immune- and inflammation-related signatures. Furthermore, SCLC shows phenotypic plasticity, including neuroendocrine-to-non-neuroendocrine transition driven by NOTCH signalling, which is associated with disease progression, chemoresistance and immune modulation and, in mouse models, with metastasis. Although these features pose substantial challenges, understanding the molecular vulnerabilities of transcription factor subtypes, the functional relevance of plasticity and cell cooperation offer opportunities for personalized therapies informed by liquid and tissue biomarkers.
Indexed as
Identifiers
40211072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.